Skip to main content

Advanced lipid testing

While standard lipid screening plays an important role in risk assessment, residual cardiovascular risk can still be significant despite management of traditional risk factors.1

Recent data suggests that even after statin therapy, residual risk still exists in many patients.2

Going beyond standard lipid panels to assess lipoprotein and apolipoprotein risk factors may provide deeper insights into the residual risk of your patients.

Patients who may benefit from advanced testing include those with:

  • Established CVD
  • Diabetes
  • Hypertension
  • Metabolic syndrome
  • Elevated LDL-C >=190 mg/dL
  • >=5% estimated ASCVD risk
  • Other traditional risk factors, including
  • Age (men >45 years; post-menopausal women)
  • Family history of premature onset of CVD
  • Unhealthy diet, excessive alcohol intake, smoking, and/or stress
  • Obesity
  • Low HDL-C

Do more to identify residual risk

Cardiovascular risk assessment has evolved beyond lipid values to include inflammation, lipoprotein subfractions, and apolipoproteins. With deeper insights, you can take further action to help reduce your patients’ risk for adverse cardiovascular events.

Learn more

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.




  1. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997;95(1):69-75.
  2. National Cholesterol Education Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.